- GLP-2 and GLP-1 are released from the same gut cells but act on different receptors. GLP-2 is linked to growth of the intestinal lining; GLP-1 to insulin release and appetite.
- Teduglutide (Gattex, Revestive), a GLP-2 analog, is FDA-approved for short bowel syndrome in people who depend on intravenous nutrition.
- A 2025 meta-analysis in Clinical Nutrition reported that 64% of patients reduced intravenous support by more than 20% at six months, and that 31% were fully weaned after two or more years.
- In glepaglutide's phase 3 trial, only one of the two treatment arms met its primary endpoint; FDA did not approve it in December 2024.
- No trial has tested GLP-2 drugs in people without intestinal failure, and no study has tested whether any gene variant changes response.
GLP-2 is released from the same gut cells as GLP-1, at the same time, every time you eat. GLP-1 became the basis of the best-known drug class of the decade. GLP-2 became the basis of a drug for people whose intestines have largely failed. Here is what GLP-2 does and what its trials found.
This page is education about published research and an approved drug. It does not recommend any GLP-2 product, and it is not medical advice. Teduglutide is a prescription drug for a specific rare condition.
Share of short bowel syndrome patients on teduglutide who reduced intravenous support by more than 20% at six months, in a 2025 systematic review and meta-analysis in Clinical Nutrition covering 23 studies.
What does GLP-2 do in the gut?
The small intestine is lined with finger-like projections called villi, which increase the surface available for absorbing nutrients. GLP-2 is released by L-cells in the gut wall in response to food, and it is linked to growth and maintenance of that lining.
Its receptor sits mainly on nerves in the gut wall and on support cells beneath the lining rather than on the lining cells themselves. Activating those cells releases growth signals that, in research, are linked to longer villi, tighter junctions between lining cells and increased intestinal blood flow. A 2020 study in Frontiers in Immunology reported that GLP-2 reduced gut permeability driven by a bacterial toxin in a laboratory model.
How is GLP-2 different from GLP-1?
Both are cut from the same parent protein, proglucagon, and released together. They then act on different receptors and have largely different effects.
GLP-1
- Increases insulin release when blood sugar is high
- Slows stomach emptying
- Reduces appetite through the brain
GLP-2
- Linked to growth of the intestinal lining
- Linked to increased intestinal blood flow
- No direct insulin or appetite effect
What did the human trials find?
GLP-2 analogs have been tested in short bowel syndrome, a condition in which so much intestine has been lost or damaged that people depend on intravenous nutrition.
"At six months, 64% of patients achieved a greater-than-20% reduction in parenteral support volume. After two or more years of treatment, that response rate climbed to 73%. The most striking finding: complete independence from IV nutrition rose from 13% at six months to 31% with long-term treatment."
Systematic review and meta-analysis, Clinical Nutrition, 2025
| Analog | Study | Population | What was reported |
|---|---|---|---|
| Teduglutide (Gattex) | Meta-analysis, Clinical Nutrition 2025 | Short bowel syndrome on intravenous support | 64% response at six months; 31% fully weaned after two or more years |
| Glepaglutide | Phase 3 RCT, Gastroenterology 2025 | Short bowel syndrome on intravenous support | One treatment arm reduced weekly intravenous volume more than placebo (5.13 vs 2.85 litres); the other arm did not differ significantly from placebo |
| Apraglutide | Phase 2, JPEN 2022 | Short bowel syndrome | Improved fluid absorption and lower intravenous volume |
Gattex is approved in the US for adults and children with short bowel syndrome who depend on parenteral support, and it is prescribed and monitored by a specialist team. FDA did not approve glepaglutide in December 2024, and neither glepaglutide nor apraglutide is approved.
Share of short bowel syndrome patients fully independent of intravenous nutrition after two or more years on teduglutide, up from 13% at six months, per the 2025 Clinical Nutrition meta-analysis.
What are the safety concerns?
Because GLP-2 drives growth of intestinal tissue, the main theoretical concern is whether it could encourage growth of abnormal tissue. The Gattex label includes colonoscopy surveillance requirements and warns about use in people with active or recent cancer. In the trial population, followed for up to 30 months, no rise in bowel cancer above background rates was seen. That is reassuring for that population but does not establish safety in others.
No trial has tested a GLP-2 drug in people without intestinal failure, so there is no evidence on benefit or long-term safety in people with milder gut symptoms.
What is the regulatory status?
Teduglutide is the only FDA-approved GLP-2 analog. It is a prescription drug for short bowel syndrome and is not something US pharmacies may compound as a copy of the approved product. FDA treats unapproved GLP-2 products as unapproved drugs when they are marketed for people.
What does research say about food and GLP-2?
The body's own GLP-2 release responds to food. In research, short-chain fatty acids such as butyrate, produced when gut bacteria ferment fibre, stimulate L-cells, as do some protein fragments and fats that reach the lower intestine. The concentrations reached this way are far below those of the drugs, and no trial has shown that diet-driven GLP-2 changes produce the effects seen with teduglutide.
What genetics research says
Several genes involved in gut inflammation and barrier function vary between people. TLR4 rs4986790 affects a receptor that detects bacterial toxins and has been linked to differences in inflammatory response. MUC2 encodes the main protein of the protective mucus layer and has been studied in inflammatory bowel conditions. IL6 rs1800795 affects a central inflammation signal.
No study has tested whether any of these genotypes changes response to a GLP-2 drug. A DNA report can show which versions you carry and what the gut research found; it cannot predict how a GLP-2 drug would work for you.
Verdict: GLP-2 is a gut hormone with a clear role in the intestinal lining and an approved drug, teduglutide, with solid trial data in short bowel syndrome. That evidence is specific to intestinal failure. There are no trials in people with milder gut problems, and no genetic predictor of response has been tested.
Watch
What clinicians and researchers say about GLP-2
Frequently asked questions
What is GLP-2 and how is it different from GLP-1?
GLP-2 and GLP-1 are both released from L-cells in the gut wall and cut from the same parent protein. They act on different receptors. GLP-1 increases insulin release, slows stomach emptying and reduces appetite. GLP-2 is linked to growth of the intestinal lining and increased intestinal blood flow.
Is there an approved GLP-2 drug?
Yes. Teduglutide (Gattex in the US, Revestive in Europe) is approved for short bowel syndrome in people who depend on intravenous nutrition. It is a prescription drug prescribed and monitored by specialist teams.
What did the teduglutide trials find?
A 2025 meta-analysis in Clinical Nutrition reported that 64% of patients reduced intravenous support by more than 20% at six months, and that 31% were fully independent of intravenous nutrition after two or more years, up from 13% at six months.
Has GLP-2 been tested for leaky gut or milder gut problems?
No. The trials were in short bowel syndrome. No trial has tested a GLP-2 drug in people without intestinal failure, so benefit and long-term safety in that population are unknown.
Does GLP-2 carry a cancer risk?
Because it drives growth of intestinal tissue, there is a theoretical concern. The Gattex label requires colonoscopy surveillance and warns about use in people with active or recent cancer. No rise in bowel cancer above background rates was seen in the trial population over up to 30 months.
Do genes affect response to GLP-2 drugs?
No study has tested that. TLR4, MUC2 and IL6 variants have been studied in gut inflammation, but none has been tested as a predictor of response to a GLP-2 drug.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.